Phibro Animal Health Corporation (NASDAQ:PAHC) Receives $37.50 Consensus PT from Analysts

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $42.40.

PAHC has been the topic of several recent analyst reports. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, Citigroup initiated coverage on Phibro Animal Health in a report on Wednesday. They issued a “neutral” rating and a $62.00 price target for the company.

Phibro Animal Health Trading Down 2.1%

PAHC stock opened at $53.88 on Friday. The firm has a fifty day moving average price of $53.29 and a 200 day moving average price of $44.96. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $60.08. The firm has a market cap of $2.18 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 0.84 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio is 21.33%.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $54.64, for a total transaction of $384,665.60. Following the completion of the sale, the chief executive officer directly owned 117,000 shares of the company’s stock, valued at approximately $6,392,880. This trade represents a 5.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 316,205 shares of company stock valued at $15,487,684 in the last quarter. 50.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Several large investors have recently made changes to their positions in the stock. 1620 Investment Advisors Inc. boosted its stake in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after buying an additional 295 shares during the period. Farther Finance Advisors LLC grew its holdings in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares in the last quarter. Rothschild Investment LLC increased its position in shares of Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares during the last quarter. Hughes Financial Services LLC acquired a new stake in shares of Phibro Animal Health in the 3rd quarter valued at $40,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health during the 3rd quarter worth $61,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.